卡格列净对心力衰竭的影响  

Effect of canagliflozin on heart failure

作　　者：胡志明 欧阳家和 李延菁 朱凌燕[1] Hu Zhiming;Ouyang Jiahe;Li Yanjing;Zhu Lingyan(Department of Endocrinology,The First Affiliated Hospital of Nanchang University;The First College of Clinical Medicine,Nanchang University)

机构地区：[1]南昌大学第一附属医院内分泌科,南昌330006 [2]南昌大学第一临床医学院,南昌330006

出　　处：《重庆医科大学学报》2021年第2期142-145,共4页Journal of Chongqing Medical University

基　　金：国家自然科学基金资助项目(编号:81860153);江西省教育厅重点资助项目(编号:GJJ180021)。

摘　　要：卡格列净是一种活性小分子钠-葡萄糖协同转运蛋白-2(sodium-glucose co-transporter type 2,SGLT2)抑制剂,因其独特的作用机制成为近年来糖尿病研究的新热点。卡格列净不仅具有降低血糖及糖化血红蛋白的作用,还有其他额外效应,如减轻体质量、降低血压、抑制炎症反应和改善心血管结局等,提示其可能对心力衰竭有直接或间接保护效应。心力衰竭是糖尿病最常见的终末事件之一,这使得卡格列净在心力衰竭的应用中有广阔前景。本研究就卡格列净对心力衰竭影响的可能机制作一综述。Canagliflozin,an active small molecule sodium-glucose co-transporter type 2(SGLT2)inhibitor,become a hot topic to treat diabetes mellitus because of their unique mechanism.Canagliflozin not only decreases plasma glucose level and HbA1 c,but also has some extra therapeutic benefits,such as losing the body weight,lowering blood pressure,suppressing inflammatory response and improving cardiovascular outcomes,so as to suggest its direct or indirect protective effect on heart failure.Heart failure is one of the most common end-events of diabetes mellitus,which brings a promising application in heart failure.This article reviewed the possible mechanism of the effect of canagliflozin on heart failure.

关 键 词：糖尿病 钠-葡萄糖协同转运蛋白-2抑制剂 卡格列净 心力衰竭 

分 类 号：R977.15[医药卫生—药品]